nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0305	0.0443	CbGbCtD
Lapatinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0276	0.04	CbGbCtD
Lapatinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0276	0.04	CbGbCtD
Lapatinib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0265	0.0385	CbGbCtD
Lapatinib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0265	0.0385	CbGbCtD
Lapatinib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0262	0.038	CbGbCtD
Lapatinib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0246	0.0357	CbGbCtD
Lapatinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0238	0.0346	CbGbCtD
Lapatinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0231	0.0336	CbGbCtD
Lapatinib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0223	0.0323	CbGbCtD
Lapatinib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0223	0.0323	CbGbCtD
Lapatinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0209	0.0303	CbGbCtD
Lapatinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0209	0.0303	CbGbCtD
Lapatinib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0201	0.0292	CbGbCtD
Lapatinib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0201	0.0292	CbGbCtD
Lapatinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0199	0.0288	CbGbCtD
Lapatinib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0193	0.028	CbGbCtD
Lapatinib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0192	0.0279	CbGbCtD
Lapatinib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0187	0.0271	CbGbCtD
Lapatinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.018	0.0261	CbGbCtD
Lapatinib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0169	0.0245	CbGbCtD
Lapatinib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0169	0.0245	CbGbCtD
Lapatinib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0162	0.0235	CbGbCtD
Lapatinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0155	0.0225	CbGbCtD
Lapatinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0151	0.0218	CbGbCtD
Lapatinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0136	0.0197	CbGbCtD
Lapatinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0136	0.0197	CbGbCtD
Lapatinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.013	0.0189	CbGbCtD
Lapatinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0127	0.0184	CbGbCtD
Lapatinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0119	0.0173	CbGbCtD
Lapatinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0119	0.0173	CbGbCtD
Lapatinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0156	CbGbCtD
Lapatinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0156	CbGbCtD
Lapatinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0101	0.0146	CbGbCtD
Lapatinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00929	0.0135	CbGbCtD
Lapatinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00902	0.0131	CbGbCtD
Lapatinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00815	0.0118	CbGbCtD
Lapatinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00815	0.0118	CbGbCtD
Lapatinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00782	0.0113	CbGbCtD
Lapatinib—TAP1—blood—acquired immunodeficiency syndrome	0.0022	0.0288	CbGeAlD
Lapatinib—TAP1—bone marrow—acquired immunodeficiency syndrome	0.00212	0.0278	CbGeAlD
Lapatinib—TAP1—spinal cord—acquired immunodeficiency syndrome	0.00212	0.0277	CbGeAlD
Lapatinib—ERBB2—skin of body—acquired immunodeficiency syndrome	0.0021	0.0276	CbGeAlD
Lapatinib—PIK3C2B—blood—acquired immunodeficiency syndrome	0.00206	0.027	CbGeAlD
Lapatinib—TAP1—vagina—acquired immunodeficiency syndrome	0.00204	0.0267	CbGeAlD
Lapatinib—PIK3C2B—bone marrow—acquired immunodeficiency syndrome	0.00199	0.0261	CbGeAlD
Lapatinib—PIK3C2B—spinal cord—acquired immunodeficiency syndrome	0.00199	0.026	CbGeAlD
Lapatinib—TAP1—lung—acquired immunodeficiency syndrome	0.00192	0.0252	CbGeAlD
Lapatinib—PIK3C2B—vagina—acquired immunodeficiency syndrome	0.00191	0.025	CbGeAlD
Lapatinib—PIK3C2B—lung—acquired immunodeficiency syndrome	0.00181	0.0237	CbGeAlD
Lapatinib—ERBB2—lymphoid tissue—acquired immunodeficiency syndrome	0.0017	0.0223	CbGeAlD
Lapatinib—ERBB2—digestive system—acquired immunodeficiency syndrome	0.00168	0.022	CbGeAlD
Lapatinib—PIK3C2B—nervous system—acquired immunodeficiency syndrome	0.00167	0.0219	CbGeAlD
Lapatinib—PIK3C2B—central nervous system—acquired immunodeficiency syndrome	0.00161	0.0211	CbGeAlD
Lapatinib—ERBB2—blood—acquired immunodeficiency syndrome	0.0016	0.021	CbGeAlD
Lapatinib—ERBB4—spinal cord—acquired immunodeficiency syndrome	0.00154	0.0202	CbGeAlD
Lapatinib—PI4KB—blood—acquired immunodeficiency syndrome	0.0015	0.0197	CbGeAlD
Lapatinib—ERBB4—vagina—acquired immunodeficiency syndrome	0.00149	0.0195	CbGeAlD
Lapatinib—PI4KB—bone marrow—acquired immunodeficiency syndrome	0.00145	0.019	CbGeAlD
Lapatinib—PI4KB—spinal cord—acquired immunodeficiency syndrome	0.00145	0.019	CbGeAlD
Lapatinib—ERBB2—lung—acquired immunodeficiency syndrome	0.00141	0.0184	CbGeAlD
Lapatinib—ERBB4—lung—acquired immunodeficiency syndrome	0.00141	0.0184	CbGeAlD
Lapatinib—PI4KB—vagina—acquired immunodeficiency syndrome	0.00139	0.0182	CbGeAlD
Lapatinib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00136	0.0178	CbGeAlD
Lapatinib—TAP1—brain—acquired immunodeficiency syndrome	0.00136	0.0178	CbGeAlD
Lapatinib—TAP1—lymph node—acquired immunodeficiency syndrome	0.00132	0.0172	CbGeAlD
Lapatinib—PI4KB—lung—acquired immunodeficiency syndrome	0.00132	0.0172	CbGeAlD
Lapatinib—ERBB2—nervous system—acquired immunodeficiency syndrome	0.0013	0.0171	CbGeAlD
Lapatinib—ERBB4—nervous system—acquired immunodeficiency syndrome	0.0013	0.0171	CbGeAlD
Lapatinib—PIK3C2B—brain—acquired immunodeficiency syndrome	0.00128	0.0168	CbGeAlD
Lapatinib—ERBB4—central nervous system—acquired immunodeficiency syndrome	0.00125	0.0164	CbGeAlD
Lapatinib—ERBB2—central nervous system—acquired immunodeficiency syndrome	0.00125	0.0164	CbGeAlD
Lapatinib—PIK3C2B—lymph node—acquired immunodeficiency syndrome	0.00124	0.0162	CbGeAlD
Lapatinib—PI4KB—nervous system—acquired immunodeficiency syndrome	0.00122	0.016	CbGeAlD
Lapatinib—EGFR—lung—acquired immunodeficiency syndrome	0.00119	0.0156	CbGeAlD
Lapatinib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00119	0.0156	CbGeAlD
Lapatinib—PI4KB—central nervous system—acquired immunodeficiency syndrome	0.00117	0.0154	CbGeAlD
Lapatinib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.00107	0.0141	CbGeAlD
Lapatinib—ERBB2—brain—acquired immunodeficiency syndrome	0.000995	0.013	CbGeAlD
Lapatinib—ERBB4—brain—acquired immunodeficiency syndrome	0.000995	0.013	CbGeAlD
Lapatinib—ERBB2—lymph node—acquired immunodeficiency syndrome	0.000961	0.0126	CbGeAlD
Lapatinib—PI4KB—brain—acquired immunodeficiency syndrome	0.000932	0.0122	CbGeAlD
Lapatinib—PI4KB—lymph node—acquired immunodeficiency syndrome	0.0009	0.0118	CbGeAlD
Lapatinib—EGFR—brain—acquired immunodeficiency syndrome	0.000843	0.011	CbGeAlD
Lapatinib—EGFR—lymph node—acquired immunodeficiency syndrome	0.000815	0.0107	CbGeAlD
Lapatinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000805	0.0106	CbGeAlD
Lapatinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00057	0.00747	CbGeAlD
Lapatinib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000524	0.00686	CbGeAlD
Lapatinib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000499	0.00654	CbGeAlD
Lapatinib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000463	0.00606	CbGeAlD
Lapatinib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000436	0.00571	CbGeAlD
Lapatinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000413	0.00541	CbGeAlD
Lapatinib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000404	0.00529	CbGeAlD
Lapatinib—CYP3A5—blood—acquired immunodeficiency syndrome	0.000393	0.00515	CbGeAlD
Lapatinib—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000364	0.00478	CbGeAlD
Lapatinib—CYP3A5—lung—acquired immunodeficiency syndrome	0.000345	0.00452	CbGeAlD
Lapatinib—Gefitinib—ALB—acquired immunodeficiency syndrome	0.000316	1	CrCbGaD
Lapatinib—ABCB1—retina—acquired immunodeficiency syndrome	0.000312	0.00409	CbGeAlD
Lapatinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00031	0.00406	CbGeAlD
Lapatinib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000295	0.00387	CbGeAlD
Lapatinib—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000287	0.00148	CcSEcCtD
Lapatinib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000287	0.00148	CcSEcCtD
Lapatinib—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000286	0.00148	CcSEcCtD
Lapatinib—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000285	0.00147	CcSEcCtD
Lapatinib—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000284	0.00147	CcSEcCtD
Lapatinib—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000284	0.00146	CcSEcCtD
Lapatinib—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000283	0.00146	CcSEcCtD
Lapatinib—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000283	0.00146	CcSEcCtD
Lapatinib—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.00145	CcSEcCtD
Lapatinib—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.00028	0.00145	CcSEcCtD
Lapatinib—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000279	0.00144	CcSEcCtD
Lapatinib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000279	0.00144	CcSEcCtD
Lapatinib—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000278	0.00144	CcSEcCtD
Lapatinib—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.000278	0.00144	CcSEcCtD
Lapatinib—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.00143	CcSEcCtD
Lapatinib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000276	0.00143	CcSEcCtD
Lapatinib—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.000276	0.00143	CcSEcCtD
Lapatinib—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000276	0.00143	CcSEcCtD
Lapatinib—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000276	0.00143	CcSEcCtD
Lapatinib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000276	0.00143	CcSEcCtD
Lapatinib—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000275	0.00142	CcSEcCtD
Lapatinib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000275	0.00142	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000275	0.00142	CcSEcCtD
Lapatinib—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000275	0.00142	CcSEcCtD
Lapatinib—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.000275	0.00142	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.00142	CcSEcCtD
Lapatinib—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000274	0.00142	CcSEcCtD
Lapatinib—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000274	0.00141	CcSEcCtD
Lapatinib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000273	0.00141	CcSEcCtD
Lapatinib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000273	0.00141	CcSEcCtD
Lapatinib—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000273	0.00141	CcSEcCtD
Lapatinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000272	0.00141	CcSEcCtD
Lapatinib—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000271	0.0014	CcSEcCtD
Lapatinib—CYP2C8—brain—acquired immunodeficiency syndrome	0.00027	0.00354	CbGeAlD
Lapatinib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00027	0.0014	CcSEcCtD
Lapatinib—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000269	0.00139	CcSEcCtD
Lapatinib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.00138	CcSEcCtD
Lapatinib—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000267	0.00138	CcSEcCtD
Lapatinib—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00138	CcSEcCtD
Lapatinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000266	0.00137	CcSEcCtD
Lapatinib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000265	0.00137	CcSEcCtD
Lapatinib—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000265	0.00137	CcSEcCtD
Lapatinib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000264	0.00137	CcSEcCtD
Lapatinib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000264	0.00137	CcSEcCtD
Lapatinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.00136	CcSEcCtD
Lapatinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000262	0.00135	CcSEcCtD
Lapatinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00026	0.00134	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00026	0.00134	CcSEcCtD
Lapatinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00026	0.00134	CcSEcCtD
Lapatinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00026	0.00134	CcSEcCtD
Lapatinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000258	0.00133	CcSEcCtD
Lapatinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000258	0.00133	CcSEcCtD
Lapatinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.00133	CcSEcCtD
Lapatinib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000257	0.00133	CcSEcCtD
Lapatinib—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000256	0.00132	CcSEcCtD
Lapatinib—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000256	0.00132	CcSEcCtD
Lapatinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000256	0.00132	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000256	0.00132	CcSEcCtD
Lapatinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000255	0.00132	CcSEcCtD
Lapatinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000254	0.00131	CcSEcCtD
Lapatinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000254	0.00131	CcSEcCtD
Lapatinib—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.00131	CcSEcCtD
Lapatinib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000254	0.00131	CcSEcCtD
Lapatinib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.0013	CcSEcCtD
Lapatinib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000252	0.0013	CcSEcCtD
Lapatinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000252	0.0013	CcSEcCtD
Lapatinib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000252	0.0013	CcSEcCtD
Lapatinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000252	0.0013	CcSEcCtD
Lapatinib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000251	0.00129	CcSEcCtD
Lapatinib—Headache—Didanosine—acquired immunodeficiency syndrome	0.00025	0.00129	CcSEcCtD
Lapatinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00025	0.00129	CcSEcCtD
Lapatinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00025	0.00129	CcSEcCtD
Lapatinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000249	0.00129	CcSEcCtD
Lapatinib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000247	0.00128	CcSEcCtD
Lapatinib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000247	0.00127	CcSEcCtD
Lapatinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000247	0.00127	CcSEcCtD
Lapatinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.00127	CcSEcCtD
Lapatinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000246	0.00127	CcSEcCtD
Lapatinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000246	0.00127	CcSEcCtD
Lapatinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000245	0.00127	CcSEcCtD
Lapatinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000245	0.00127	CcSEcCtD
Lapatinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.00126	CcSEcCtD
Lapatinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.00126	CcSEcCtD
Lapatinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000244	0.00126	CcSEcCtD
Lapatinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.00126	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.00125	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000242	0.00125	CcSEcCtD
Lapatinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000242	0.00125	CcSEcCtD
Lapatinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000242	0.00125	CcSEcCtD
Lapatinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.00125	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000241	0.00125	CcSEcCtD
Lapatinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000241	0.00125	CcSEcCtD
Lapatinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00024	0.00124	CcSEcCtD
Lapatinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00024	0.00124	CcSEcCtD
Lapatinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.00024	0.00314	CbGeAlD
Lapatinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000238	0.00123	CcSEcCtD
Lapatinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000238	0.00123	CcSEcCtD
Lapatinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000237	0.00123	CcSEcCtD
Lapatinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000237	0.00123	CcSEcCtD
Lapatinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.00122	CcSEcCtD
Lapatinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000236	0.00122	CcSEcCtD
Lapatinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000235	0.00122	CcSEcCtD
Lapatinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000235	0.00122	CcSEcCtD
Lapatinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000234	0.00121	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.00121	CcSEcCtD
Lapatinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000233	0.0012	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000231	0.00119	CcSEcCtD
Lapatinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000231	0.00302	CbGeAlD
Lapatinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.00023	0.00119	CcSEcCtD
Lapatinib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00023	0.00119	CcSEcCtD
Lapatinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00023	0.00119	CcSEcCtD
Lapatinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000229	0.00118	CcSEcCtD
Lapatinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000229	0.00118	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000229	0.00118	CcSEcCtD
Lapatinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000228	0.00118	CcSEcCtD
Lapatinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000228	0.00118	CcSEcCtD
Lapatinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000228	0.00118	CcSEcCtD
Lapatinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.00117	CcSEcCtD
Lapatinib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000227	0.00117	CcSEcCtD
Lapatinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000226	0.00117	CcSEcCtD
Lapatinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.00117	CcSEcCtD
Lapatinib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000225	0.00116	CcSEcCtD
Lapatinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.00116	CcSEcCtD
Lapatinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.00116	CcSEcCtD
Lapatinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000224	0.00116	CcSEcCtD
Lapatinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.00115	CcSEcCtD
Lapatinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000223	0.00115	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.00115	CcSEcCtD
Lapatinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000222	0.00291	CbGeAlD
Lapatinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000222	0.00114	CcSEcCtD
Lapatinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000221	0.00114	CcSEcCtD
Lapatinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000221	0.00114	CcSEcCtD
Lapatinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000221	0.00114	CcSEcCtD
Lapatinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.00022	0.00114	CcSEcCtD
Lapatinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000219	0.00287	CbGeAlD
Lapatinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000219	0.00113	CcSEcCtD
Lapatinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000218	0.00113	CcSEcCtD
Lapatinib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000217	0.00112	CcSEcCtD
Lapatinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000217	0.00112	CcSEcCtD
Lapatinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.00112	CcSEcCtD
Lapatinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.00112	CcSEcCtD
Lapatinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000216	0.00112	CcSEcCtD
Lapatinib—Rash—Abacavir—acquired immunodeficiency syndrome	0.000216	0.00111	CcSEcCtD
Lapatinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000215	0.00111	CcSEcCtD
Lapatinib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.00111	CcSEcCtD
Lapatinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.00111	CcSEcCtD
Lapatinib—Headache—Abacavir—acquired immunodeficiency syndrome	0.000214	0.00111	CcSEcCtD
Lapatinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.0011	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000214	0.0011	CcSEcCtD
Lapatinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000213	0.0011	CcSEcCtD
Lapatinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000213	0.0011	CcSEcCtD
Lapatinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000212	0.00109	CcSEcCtD
Lapatinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000211	0.00109	CcSEcCtD
Lapatinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000209	0.00108	CcSEcCtD
Lapatinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.00108	CcSEcCtD
Lapatinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.00108	CcSEcCtD
Lapatinib—ABCB1—blood—acquired immunodeficiency syndrome	0.000209	0.00274	CbGeAlD
Lapatinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000207	0.00107	CcSEcCtD
Lapatinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000207	0.00107	CcSEcCtD
Lapatinib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000207	0.00107	CcSEcCtD
Lapatinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000206	0.00107	CcSEcCtD
Lapatinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000206	0.00107	CcSEcCtD
Lapatinib—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000206	0.00106	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000206	0.00106	CcSEcCtD
Lapatinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00106	CcSEcCtD
Lapatinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000204	0.00105	CcSEcCtD
Lapatinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000204	0.00105	CcSEcCtD
Lapatinib—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000203	0.00105	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000202	0.00105	CcSEcCtD
Lapatinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000202	0.00104	CcSEcCtD
Lapatinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000202	0.00265	CbGeAlD
Lapatinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000201	0.00264	CbGeAlD
Lapatinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000201	0.00104	CcSEcCtD
Lapatinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.00104	CcSEcCtD
Lapatinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.00104	CcSEcCtD
Lapatinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.00103	CcSEcCtD
Lapatinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.00103	CcSEcCtD
Lapatinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000198	0.00102	CcSEcCtD
Lapatinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000196	0.00101	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.00101	CcSEcCtD
Lapatinib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.00101	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000195	0.00101	CcSEcCtD
Lapatinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.00101	CcSEcCtD
Lapatinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000195	0.001	CcSEcCtD
Lapatinib—ABCB1—vagina—acquired immunodeficiency syndrome	0.000194	0.00254	CbGeAlD
Lapatinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000996	CcSEcCtD
Lapatinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000991	CcSEcCtD
Lapatinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000192	0.000991	CcSEcCtD
Lapatinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000192	0.00099	CcSEcCtD
Lapatinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.00099	CcSEcCtD
Lapatinib—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00019	0.000982	CcSEcCtD
Lapatinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00019	0.000982	CcSEcCtD
Lapatinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00019	0.000981	CcSEcCtD
Lapatinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000189	0.000978	CcSEcCtD
Lapatinib—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000189	0.000975	CcSEcCtD
Lapatinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000187	0.000968	CcSEcCtD
Lapatinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000187	0.000966	CcSEcCtD
Lapatinib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000187	0.000964	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000186	0.00096	CcSEcCtD
Lapatinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000186	0.000958	CcSEcCtD
Lapatinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.000957	CcSEcCtD
Lapatinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000185	0.000953	CcSEcCtD
Lapatinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000951	CcSEcCtD
Lapatinib—ABCB1—lung—acquired immunodeficiency syndrome	0.000183	0.0024	CbGeAlD
Lapatinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000182	0.000939	CcSEcCtD
Lapatinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000181	0.000936	CcSEcCtD
Lapatinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000179	0.000926	CcSEcCtD
Lapatinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000179	0.000925	CcSEcCtD
Lapatinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000921	CcSEcCtD
Lapatinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000178	0.000921	CcSEcCtD
Lapatinib—Rash—Indinavir—acquired immunodeficiency syndrome	0.000177	0.000913	CcSEcCtD
Lapatinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000177	0.000912	CcSEcCtD
Lapatinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000909	CcSEcCtD
Lapatinib—Headache—Indinavir—acquired immunodeficiency syndrome	0.000176	0.000907	CcSEcCtD
Lapatinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000173	0.000896	CcSEcCtD
Lapatinib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.000892	CcSEcCtD
Lapatinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000879	CcSEcCtD
Lapatinib—ABCB1—nervous system—acquired immunodeficiency syndrome	0.00017	0.00222	CbGeAlD
Lapatinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000168	0.00087	CcSEcCtD
Lapatinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000168	0.000869	CcSEcCtD
Lapatinib—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000167	0.000863	CcSEcCtD
Lapatinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000167	0.000862	CcSEcCtD
Lapatinib—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000167	0.00086	CcSEcCtD
Lapatinib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000858	CcSEcCtD
Lapatinib—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000166	0.000857	CcSEcCtD
Lapatinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.000856	CcSEcCtD
Lapatinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000163	0.00214	CbGeAlD
Lapatinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000162	0.000836	CcSEcCtD
Lapatinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000161	0.000832	CcSEcCtD
Lapatinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00016	0.000828	CcSEcCtD
Lapatinib—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00016	0.000825	CcSEcCtD
Lapatinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00016	0.000825	CcSEcCtD
Lapatinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000824	CcSEcCtD
Lapatinib—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.00082	CcSEcCtD
Lapatinib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000819	CcSEcCtD
Lapatinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000157	0.000813	CcSEcCtD
Lapatinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000154	0.000798	CcSEcCtD
Lapatinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000154	0.000797	CcSEcCtD
Lapatinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.000786	CcSEcCtD
Lapatinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000151	0.000778	CcSEcCtD
Lapatinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000149	0.00077	CcSEcCtD
Lapatinib—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000763	CcSEcCtD
Lapatinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000763	CcSEcCtD
Lapatinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000147	0.000761	CcSEcCtD
Lapatinib—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000758	CcSEcCtD
Lapatinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000143	0.000741	CcSEcCtD
Lapatinib—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000735	CcSEcCtD
Lapatinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000734	CcSEcCtD
Lapatinib—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.00073	CcSEcCtD
Lapatinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.000719	CcSEcCtD
Lapatinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000137	0.000707	CcSEcCtD
Lapatinib—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000136	0.000701	CcSEcCtD
Lapatinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000136	0.0007	CcSEcCtD
Lapatinib—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000696	CcSEcCtD
Lapatinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000692	CcSEcCtD
Lapatinib—EGFR—SHP2 signaling—IL2—acquired immunodeficiency syndrome	0.000131	0.00323	CbGpPWpGaD
Lapatinib—EGFR—GRB2 events in ERBB2 signaling—IL6—acquired immunodeficiency syndrome	0.00013	0.00322	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.00013	0.00322	CbGpPWpGaD
Lapatinib—EGFR—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	0.00013	0.0032	CbGpPWpGaD
Lapatinib—ABCB1—brain—acquired immunodeficiency syndrome	0.00013	0.0017	CbGeAlD
Lapatinib—ERBB4—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000129	0.00319	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000129	0.00318	CbGpPWpGaD
Lapatinib—TAP1—Immune System—CD40LG—acquired immunodeficiency syndrome	0.000128	0.00316	CbGpPWpGaD
Lapatinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000128	0.00066	CcSEcCtD
Lapatinib—PI4KB—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000128	0.00315	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000127	0.00313	CbGpPWpGaD
Lapatinib—TAP1—Immune System—CD8A—acquired immunodeficiency syndrome	0.000126	0.00312	CbGpPWpGaD
Lapatinib—TAP1—Immune System—CSF2—acquired immunodeficiency syndrome	0.000126	0.00312	CbGpPWpGaD
Lapatinib—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000125	0.00164	CbGeAlD
Lapatinib—EGFR—SHC1 events in ERBB2 signaling—IL6—acquired immunodeficiency syndrome	0.000124	0.00306	CbGpPWpGaD
Lapatinib—TAP1—Immune System—HLA-B—acquired immunodeficiency syndrome	0.000122	0.003	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	0.00012	0.00296	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—CD79A—acquired immunodeficiency syndrome	0.000117	0.00288	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—CCR2—acquired immunodeficiency syndrome	0.000116	0.00286	CbGpPWpGaD
Lapatinib—EGFR—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	0.000115	0.00285	CbGpPWpGaD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000115	0.00283	CbGpPWpGaD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	0.000115	0.00283	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—CCR2—acquired immunodeficiency syndrome	0.000114	0.00282	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CCNT1—acquired immunodeficiency syndrome	0.000111	0.00275	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CCNT1—acquired immunodeficiency syndrome	0.00011	0.00271	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000105	0.0026	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—ACTG1—acquired immunodeficiency syndrome	0.000105	0.00258	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	0.000104	0.00257	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—ACTG1—acquired immunodeficiency syndrome	0.000103	0.00254	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	0.000103	0.00253	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	9.88e-05	0.00244	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	9.88e-05	0.00244	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	9.84e-05	0.00243	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	9.77e-05	0.00241	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	9.72e-05	0.0024	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	9.61e-05	0.00237	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	9.58e-05	0.00236	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	9.4e-05	0.00232	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	8.69e-05	0.00214	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—MBL2—acquired immunodeficiency syndrome	8.6e-05	0.00212	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—MBL2—acquired immunodeficiency syndrome	8.47e-05	0.00209	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	8.35e-05	0.00206	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	7.92e-05	0.00196	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	7.85e-05	0.00194	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	7.84e-05	0.00193	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	7.82e-05	0.00193	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.81e-05	0.00193	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.81e-05	0.00193	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	7.81e-05	0.00193	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	7.73e-05	0.00191	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	7.72e-05	0.0019	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	7.71e-05	0.0019	CbGpPWpGaD
Lapatinib—EGFR—SHP2 signaling—IL6—acquired immunodeficiency syndrome	7.7e-05	0.0019	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.69e-05	0.0019	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.69e-05	0.0019	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.61e-05	0.00188	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	7.54e-05	0.00186	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IFNG—acquired immunodeficiency syndrome	7.52e-05	0.00186	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	7.49e-05	0.00185	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	7.42e-05	0.00183	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	7.42e-05	0.00183	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	7.37e-05	0.00182	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	7.37e-05	0.00182	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.34e-05	0.00181	CbGpPWpGaD
Lapatinib—TAP1—Immune System—CD4—acquired immunodeficiency syndrome	7.26e-05	0.00179	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	7.26e-05	0.00179	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MBL2—acquired immunodeficiency syndrome	7.14e-05	0.00176	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.06e-05	0.00174	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	7.04e-05	0.00174	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	7e-05	0.00173	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	6.97e-05	0.00172	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.95e-05	0.00172	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 signaling—IL6—acquired immunodeficiency syndrome	6.93e-05	0.00171	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	6.93e-05	0.00171	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	6.9e-05	0.0017	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	6.86e-05	0.00169	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 signaling—IL6—acquired immunodeficiency syndrome	6.83e-05	0.00169	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CCR2—acquired immunodeficiency syndrome	6.75e-05	0.00166	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IL2—acquired immunodeficiency syndrome	6.68e-05	0.00165	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CCR2—acquired immunodeficiency syndrome	6.64e-05	0.00164	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.55e-05	0.00162	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	6.52e-05	0.00161	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 interactions—IL6—acquired immunodeficiency syndrome	6.52e-05	0.00161	CbGpPWpGaD
Lapatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	6.52e-05	0.00161	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	6.46e-05	0.0016	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	6.43e-05	0.00159	CbGpPWpGaD
Lapatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	6.43e-05	0.00159	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 interactions—IL6—acquired immunodeficiency syndrome	6.43e-05	0.00159	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	6.41e-05	0.00158	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.39e-05	0.00158	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	6.38e-05	0.00157	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	6.37e-05	0.00157	CbGpPWpGaD
Lapatinib—EGFR—Disease—APOBEC3G—acquired immunodeficiency syndrome	6.34e-05	0.00156	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	6.31e-05	0.00156	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	6.28e-05	0.00155	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.23e-05	0.00154	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IFNA1—acquired immunodeficiency syndrome	6.07e-05	0.0015	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IFNA1—acquired immunodeficiency syndrome	5.98e-05	0.00148	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD79A—acquired immunodeficiency syndrome	5.9e-05	0.00145	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—ALB—acquired immunodeficiency syndrome	5.88e-05	0.00145	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CXCR4—acquired immunodeficiency syndrome	5.86e-05	0.00144	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	5.81e-05	0.00143	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD79A—acquired immunodeficiency syndrome	5.81e-05	0.00143	CbGpPWpGaD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	5.78e-05	0.00143	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.78e-05	0.00143	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CXCR4—acquired immunodeficiency syndrome	5.77e-05	0.00142	CbGpPWpGaD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	5.69e-05	0.0014	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—ALB—acquired immunodeficiency syndrome	5.68e-05	0.0014	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	5.6e-05	0.00138	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	5.41e-05	0.00133	CbGpPWpGaD
Lapatinib—EGFR—Disease—CCNT1—acquired immunodeficiency syndrome	5.39e-05	0.00133	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	5.16e-05	0.00127	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ACTG1—acquired immunodeficiency syndrome	5.06e-05	0.00125	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	5.04e-05	0.00124	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.82e-05	0.00119	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD40LG—acquired immunodeficiency syndrome	4.81e-05	0.00119	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CSF2—acquired immunodeficiency syndrome	4.75e-05	0.00117	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD8A—acquired immunodeficiency syndrome	4.75e-05	0.00117	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.75e-05	0.00117	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD40LG—acquired immunodeficiency syndrome	4.73e-05	0.00117	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	4.7e-05	0.00116	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—CD4—acquired immunodeficiency syndrome	4.69e-05	0.00116	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CSF2—acquired immunodeficiency syndrome	4.68e-05	0.00116	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD8A—acquired immunodeficiency syndrome	4.68e-05	0.00116	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—CD4—acquired immunodeficiency syndrome	4.62e-05	0.00114	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-B—acquired immunodeficiency syndrome	4.57e-05	0.00113	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-B—acquired immunodeficiency syndrome	4.5e-05	0.00111	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	4.5e-05	0.00111	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	4.44e-05	0.0011	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	4.44e-05	0.0011	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	4.43e-05	0.00109	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—IL6—acquired immunodeficiency syndrome	4.38e-05	0.00108	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	4.36e-05	0.00108	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.36e-05	0.00108	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.3e-05	0.00106	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MBL2—acquired immunodeficiency syndrome	4.16e-05	0.00103	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.1e-05	0.00101	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.1e-05	0.00101	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	4.07e-05	0.00101	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.04e-05	0.000997	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.04e-05	0.000997	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—IL6—acquired immunodeficiency syndrome	4.02e-05	0.000992	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CCR5—acquired immunodeficiency syndrome	4.01e-05	0.00099	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CCR5—acquired immunodeficiency syndrome	3.95e-05	0.000975	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.95e-05	0.000974	CbGpPWpGaD
Lapatinib—TAP1—Immune System—IL6—acquired immunodeficiency syndrome	3.93e-05	0.000969	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	3.85e-05	0.000949	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	3.83e-05	0.000945	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	3.79e-05	0.000936	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	3.79e-05	0.000935	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	3.78e-05	0.000933	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	3.78e-05	0.000932	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.77e-05	0.000931	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.77e-05	0.000931	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	3.76e-05	0.000928	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.68e-05	0.000907	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	3.64e-05	0.000899	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	3.62e-05	0.000893	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.57e-05	0.000881	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	3.56e-05	0.000879	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.56e-05	0.000878	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	3.43e-05	0.000847	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.41e-05	0.000842	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	3.4e-05	0.000839	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	3.39e-05	0.000835	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	3.37e-05	0.000831	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.36e-05	0.000828	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.36e-05	0.000828	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	3.35e-05	0.000827	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	3.35e-05	0.000827	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	3.27e-05	0.000807	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CCR2—acquired immunodeficiency syndrome	3.26e-05	0.000805	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	3.15e-05	0.000778	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	3.15e-05	0.000778	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	3.15e-05	0.000778	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	3.13e-05	0.000771	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.00077	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	3.1e-05	0.000764	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	3.08e-05	0.000761	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.07e-05	0.000758	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.07e-05	0.000758	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.03e-05	0.000747	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNA1—acquired immunodeficiency syndrome	2.94e-05	0.000725	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	2.92e-05	0.00072	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.87e-05	0.000708	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD79A—acquired immunodeficiency syndrome	2.85e-05	0.000703	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.85e-05	0.000703	CbGpPWpGaD
Lapatinib—EGFR—Disease—CXCR4—acquired immunodeficiency syndrome	2.83e-05	0.000699	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IFNG—acquired immunodeficiency syndrome	2.83e-05	0.000697	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.000693	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.79e-05	0.000689	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IFNG—acquired immunodeficiency syndrome	2.78e-05	0.000687	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.77e-05	0.000683	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CD4—acquired immunodeficiency syndrome	2.73e-05	0.000674	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.7e-05	0.000666	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CD4—acquired immunodeficiency syndrome	2.69e-05	0.000663	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.55e-05	0.00063	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.53e-05	0.000625	CbGpPWpGaD
Lapatinib—ERBB2—Disease—CD4—acquired immunodeficiency syndrome	2.52e-05	0.000622	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.51e-05	0.000621	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL2—acquired immunodeficiency syndrome	2.51e-05	0.00062	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.5e-05	0.000616	CbGpPWpGaD
Lapatinib—ERBB4—Disease—CD4—acquired immunodeficiency syndrome	2.48e-05	0.000613	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL2—acquired immunodeficiency syndrome	2.47e-05	0.00061	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.33e-05	0.000575	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD40LG—acquired immunodeficiency syndrome	2.32e-05	0.000573	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.3e-05	0.000568	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CSF2—acquired immunodeficiency syndrome	2.3e-05	0.000567	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD8A—acquired immunodeficiency syndrome	2.3e-05	0.000567	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.27e-05	0.000559	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-B—acquired immunodeficiency syndrome	2.21e-05	0.000545	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.18e-05	0.000537	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.15e-05	0.00053	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.11e-05	0.00052	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.06e-05	0.000509	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.98e-05	0.000489	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.98e-05	0.000489	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—IL6—acquired immunodeficiency syndrome	1.94e-05	0.00048	CbGpPWpGaD
Lapatinib—EGFR—Disease—CCR5—acquired immunodeficiency syndrome	1.94e-05	0.000479	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.86e-05	0.000458	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.76e-05	0.000433	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.72e-05	0.000424	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000401	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.6e-05	0.000395	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.000372	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.51e-05	0.000372	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.49e-05	0.000367	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000364	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000359	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.39e-05	0.000342	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNG—acquired immunodeficiency syndrome	1.37e-05	0.000337	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000336	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.000335	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.34e-05	0.000332	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—acquired immunodeficiency syndrome	1.34e-05	0.000331	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000328	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD4—acquired immunodeficiency syndrome	1.32e-05	0.000326	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.25e-05	0.000308	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.23e-05	0.000302	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD4—acquired immunodeficiency syndrome	1.22e-05	0.000301	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL2—acquired immunodeficiency syndrome	1.21e-05	0.0003	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.54e-06	0.000236	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.4e-06	0.000232	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.85e-06	0.000194	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.81e-06	0.000193	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	7.74e-06	0.000191	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—acquired immunodeficiency syndrome	7.14e-06	0.000176	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	6.71e-06	0.000166	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—acquired immunodeficiency syndrome	6.59e-06	0.000163	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	5.99e-06	0.000148	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	5.84e-06	0.000144	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.61e-06	0.000114	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.6e-06	8.88e-05	CbGpPWpGaD
